N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof

1. A method of treating a pathology in which receptors of TRPV1 are involved in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

in which

X 1 is hydrogen, halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, cyano, C(O)NR 1 R 2 , nitro, C 1 -C 6 -thioalkyl, —S(O)—C 1 -C 6 -alkyl, —S(O) 2 —C 1 -C 6 -alkyl, SO 2 NR 1 R 2 , aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group, the aryl and heteroaryl being optionally substituted with one or more substituents selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -fluoroalkoxy, nitro or cyano group;

X 2 is hydrogen, halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxyl, cyano, C(O)NR 1 R 2 , C 1 -C 6 -thioalkyl, —S(O)—C 1 -C 6 -alkyl, —S(O) 2 —C 1 -C 6 -alkyl, SO 2 NR 1 R 2 , aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group, the aryl and the heteroaryl being optionally substituted with one or more substituents selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -fluoroalkoxy, nitro or cyano group;

X 3 and X 4 , independently of one another, are hydrogen, halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxy, cyano, C(O)NR 1 R 2 , nitro, NR 1 R 2 , C 1 -C 6 -thioalkyl, —S(O)—C 1 -C 6 -alkyl, —S(O) 2 —C 1 -C 6 -alkyl, SO 2 NR 1 R 2 , NR 3 COR 4 , NR 3 SO 2 R 5 , aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group, the aryl and the heteroaryl being optionally substituted with one or more substituents selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -fluoroalkoxy, nitro or cyano group;

Z 1 , Z 2 , Z 3 and Z 4 , independently of one another, are nitrogen or C(R 6 ) group, wherein at least one of which is nitrogen and at least one of which is C(R 6 ) group; the nitrogen atom or one of the nitrogen atoms present in the ring, defined as nitrogen in the 1-position, being optionally substituted with R 7 when the carbon atom in the 2- or 4-position with respect to this reference nitrogen is substituted with an oxo or thio group;

n is equal to 0, 1, 2 or 3;

Y is aryl or heteroaryl optionally substituted with one or more groups selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, hydroxy, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxyl, cyano, C(O)NR 1 R 2 , nitro, NR 1 R 2 , C 1 -C 6 -thioalkyl, thiol, —S(O)—C 1 -C 6 -alkyl, —S(O) 2 —C 1 -C 6 -alkyl, SO 2 NR 1 R 2 , NR 3 COR 4 , NR 3 SO 2 R 5 , aryl-C 1 -C 6 -alkylene or aryl group, the aryl and the aryl-C 1 -C 6 -alkylene being optionally substituted with one or more substituents selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -fluoroalkoxy, nitro or cyano group;

Z is a cyclic amine attached via the nitrogen atom, of formula:

in which A is C 1 -C 7 -alkylene optionally substituted with one or two groups R 8 ;

B is C 1 -C 7 -alkylene group optionally substituted with one or two groups R 9 ;

L is a bond, sulfur, oxygen, NR 10 or NR 11 ,

the carbon atoms of the cyclic amine Z being optionally substituted with one or more groups R 12 which may be identical to or different from one another;

R 1 and R 2 , independently of one another, are hydrogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group; or

R 1 and R 2 taken together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, morpholinyl, thiomorpholinyl, piperazinyl or homopiperazinyl group, this group being optionally substituted with C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group;

R 3 and R 4 , independently of one another, are hydrogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group;

R 5 is a C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group;

R 6 is hydrogen, halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxy, C 1 -C 6 -thioalkyl, —S(O)—C 1 -C 6 -alkyl, —S(O) 2 —C 1 -C 6 -alkyl, aryl, aryl-C 1 -C 6 -alkylene, heteroaryl, hydroxy, thiol, oxo or thio group;

R 7 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxy, aryl, aryl-C 1 -C 6 -alkylene or heteroaryl group;

R 8 , R 9 and R 10 are defined such that:

two groups R 8 can together form a bond or a C 1 -C 6 -alkylene group;

two groups R 9 can together form a bond or a C 1 -C 6 -alkylene group;

R 8 and R 9 can together form a bond or a C 1 -C 6 -alkylene group;

R 8 and R 10 can together form a bond or a C 1 -C 6 -alkylene group;

R 9 and R 10 can together form a bond or a C 1 -C 6 -alkylene group;

R 11 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxy, hydroxy, COOR S , C(O)NR 1 R 2 , aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group, the aryl and the heteroaryl being optionally substituted with one or more substituents selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 1 -C 6 -fluoroalkoxy, nitro or cyano group;

R 12 is fluorine, C 1 -C 6 -alkyl optionally substituted with R 13 , C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl or C 1 -C 6 -cycloalkyl-1,1-idinyl group, a C 3 -C 7 -heterocycloalkyl-1,1-idinyl group optionally substituted on a nitrogen atom with a group R 11 , or a C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C 1 -C 6 -fluoroalkoxy, C(O)NR 1 R 2 , NR 1 R 2 , NR 3 COR 4 , OC(O)NR 1 R 2 , NR 3 COOR 5 , NR 3 CONR 1 R 2 , hydroxy, thiol, oxo, thio, aryl-C 1 -C 6 -alkylene or aryl group, the aryl being optionally substituted with one or more substituents selected from halogen, C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 1 -C 6 -fluoroalkoxy, nitro or cyano group;

R 13 is a C 1 -C 6 -alkoxy, C 3 -C 7 -cycloalkoxy, C 3 -C 7 -cycloalkyl-C 1 -C 6 -alkylene-O—, C(O)NR 1 R 2 , NR 1 R 2 , NR 3 COR 4 , OC(O)NR 1 R 2 , NR 3 COOR 5 or hydroxy; and

it being possible for the nitrogen atom(s) of the compound of formula (I) to be in oxidized form;

it being possible for the sulfur atom(s) of the compound of formula (I) to be in oxidized form;

wherein said pathology is selected from the group consisting of neuropathic pain, a urological disorder, a gastrointestinal disorder, and diabetes; wherein the urological disorder is selected from the group consisting of bladder hyperactivity, bladder hyperreflexia, bladder instability, incontinence, urgent urination, urinary incontinence, cystitis, nephritic colic, pelvic hypersensitivity and pelvic pain; and the gastrointestinal disorder is selected from the group consisting of gastroesophageal reflex disorder (GERD), stomach ulcers, duodenal ulcers, functional dyspepsia, colitis, irritable bowel syndrome (IBS), Crohn's disease, pancreatitis, oesophagitis and biliary colic.

2. The method according to claim 1 , wherein X 1 , X 2 , X 3 and X 4 are selected, independently of one another, from hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -thioalkyl or —S(O) 2 —C 1 -C 6 -alkyl.

3. The method according to claim 1 , wherein

X 1 is hydrogen, halogen or C 1 -C 6 -alkyl;

X 2 is hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -fluoroalkyl or —S(O) 2 —C 1 -C 6 -alkyl;

X 3 and X 4 , independently of one another, are hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -alkoxy, NR 1 R 2 or C 1 -C 6 -thioalkyl; and

R 1 and R 2 , independently of one another, are C 1 -C 6 -alkyl.

4. The method according to claim 1 , wherein Z 1 , Z 2 , Z 3 and Z 4 are, independently of one another, nitrogen or C(R 6 ) group of which at least two of them are C(R 6 ) group; and the nitrogen atom or one of the nitrogen atoms present in the ring, defined as nitrogen in the 1-position, being optionally substituted with R 7 when the carbon atom in the 2- or 4-position with respect to this reference nitrogen is substituted with an oxo or thio group.

5. The method according to claim 4 , wherein Z 1 and Z 3 are C(R 6 ) group and Z 2 and Z 4 are nitrogen; and wherein R 6 is hydrogen.

6. The method according to claim 4 , wherein Z 1 , Z 2 , Z 3 and Z 4 are, independently of one another, nitrogen or C(R 6 ) group, one of which is nitrogen and the others are C(R 6 ) group;

and the nitrogen atom present in the cycle, defined as nitrogen in the 1-position, being optionally substituted with R 7 when the carbon atom in the 2- or 4-position with respect to this reference nitrogen is substituted with an oxo or thio group.

7. The method according to claim 6 , wherein:

Z 4 is nitrogen and Z 1 , Z 2 and Z 3 are, independently of one another, C(R 6 ) group; and wherein

R 6 is hydrogen or C 1 -C 6 -alkyl, C 1 -C 6 -fluoroalkyl or C 1 -C 6 -alkoxyl.

8. The method according to claim 1 , wherein n is equal to 1.

9. The method according to claim 1 , wherein Y is an aryl or a heteroaryl optionally substituted with one or more groups selected from halogen, C 1 -C 6 -alkyl or NR 1 R 2 ; and wherein

R 1 and R 2 taken together with the nitrogen atom to which they are attached form azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, morpholinyl, thiomorpholinyl, piperazinyl or homopiperazinyl group, this group being optionally substituted with C 1 -C 6 -alkyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 3 -alkylene, aryl-C 1 -C 6 -alkylene, aryl or heteroaryl group.

10. The method according to claim 1 , wherein:

Z is a cyclic amine attached via the nitrogen atom, of formula:

in which A is C 1 -C 4 -alkylene group optionally substituted with one or two groups R 8 ;

B is C 1 -C 4 -alkylene group optionally substituted with one or two groups R 9 ;

L is a bond or oxygen;

it being possible for the nitrogen of the cyclic amine Z to be in N-oxide form;

the carbon atoms of the cyclic amine Z being optionally substituted with a group R 12 ;

R 8 and R 9 are defined such that:

two groups R 8 can together form a bond; or

two groups R 9 can together form a bond; or

R 8 and R 9 can together form a bond;

R 12 is NR 1 R 2 , NR 3 COOR 5 or hydroxy;

R 1 and R 2 are, independently of one another, hydrogen;

R 3 is hydrogen; and

R 5 is C 1 -C 6 -alkyl.

11. The method according to claim 10 , wherein:

Z is a cyclic amine selected from azetidine, pyrrolidine, piperidine, morpholine, azabicylo[3.1.0]hexane and azabicylo[3.2.0]heptane;

it being possible for the nitrogen atom of the cyclic amine Z to be in N-oxide form;

the carbon atoms of the cyclic amine Z being optionally substituted with a group R 12 ;

R 12 is NR 1 R 2 , NR 3 COOR 5 or hydroxy;

R 1 and R 2 are, independently of one another, hydrogen;

R 3 is hydrogen; and

R 5 is C 1 -C 6 -alkyl.

12. The method according to claim 11 , wherein:

Z is a cyclic amine selected from azetidine, pyrrolidine, piperidine, morpholine, azabicylo[3.1.0]hexane and azabicylo[3.2.0]heptane;

the carbon atoms of the azetidine being optionally substituted with hydroxy;

the carbon atoms of the pyrrolidine being optionally substituted with NR 1 R 2 , NR 3 COOR 5 or hydroxy; it being possible for the nitrogen atom of the pyrrolidine to be in N-oxide form;

R 1 and R 2 are, independently of one another, hydrogen;

R 3 is hydrogen; and

R 5 is C 1 -C 6 -alkyl.

13. A compound selected from the group consisting of:

and an addition salt with an acid of said compound.

14. The method according to claim 1 , wherein the pathology is neuropathic pain.

15. The method according to claim 1 , wherein the pathology is a urological disorder or a gastrointestinal disorder; wherein the urological disorder is selected from the group consisting of bladder hyperactivity, bladder hyperreflexia, bladder instability, incontinence, urgent urination, urinary incontinence, cystitis, nephritic colic, pelvic hypersensitivity and pelvic pain; and the gastrointestinal disorder is selected from the group consisting of gastroesophageal reflux disease (GERD), stomach ulcers, duodenal ulcers, function dyspepsia, colitis, irritable bowel syndrome (IBS), Crohn's disease, pancreatitis, oesophagitis, and biliary colic.

16. The method according to claim 1 , wherein the pathology is diabetes.